Cediranib has been evaluated across numerous clinical trials ranging from Early Phase I to Phase III, investigating the drug as monotherapy and in combination regimens for metastatic colorectal cancer, alveolar soft part sarcoma, uveal melanoma, biliary tract malignancies, and ovarian cancer. Spearheaded by pharmaceutical sponsors such as AstraZeneca alongside academic and government entities like the National Cancer Institute and Cancer Research UK, these investigations span completed, active, recruiting, and terminated recruitment statuses.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04090567 | RECRUITING | Advanced Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Germline BRCA1 Gene Mutation; Germline BRCA2 Gene Mutation; HER2/Neu Negative; Metastatic Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2020-07-28 | PHASE2 |
| NCT02484404 | ACTIVE_NOT_RECRUITING | Colorectal Neoplasms; Breast Neoplasms |
National Cancer Institute (NCI) |
2015-06-29 | PHASE1; PHASE2 |
| NCT03851614 | ACTIVE_NOT_RECRUITING | Mismatch Repair Proficient Colorectal Cancer; Pancreatic Adenocarcinoma; Leiomyosarcoma |
University Health Network, Toronto |
2019-04-08 | PHASE2 |
| NCT03741426 | UNKNOWN | Renal Cell Cancer |
CCTU- Cancer Theme |
2020-07-27 | PHASE2 |
| NCT04487587 | ACTIVE_NOT_RECRUITING | Cervical Cancer |
The Clatterbridge Cancer Centre NHS Foundation Trust |
2018-10-09 | PHASE2 |
| NCT07648745 | COMPLETED | Bowel Obstruction; Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer |
Prof Gordon Jayson |
2018-05-14 | PHASE2 |
| NCT03660826 | ACTIVE_NOT_RECRUITING | Endometrial Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Endometrioid Adenocarcinoma; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 |
National Cancer Institute (NCI) |
2018-09-27 | PHASE2 |
| NCT03334617 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer |
AstraZeneca |
2017-12-18 | PHASE2 |
| NCT03278717 | UNKNOWN | Ovarian Cancer |
University College, London |
2018-06-15 | PHASE3 |
| NCT01391962 | COMPLETED | Sarcoma, Alveolar Soft Part |
National Cancer Institute (NCI) |
2011-07-18 | PHASE2 |
| NCT02502266 | ACTIVE_NOT_RECRUITING | Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma |
National Cancer Institute (NCI) |
2016-05-03 | PHASE2; PHASE3 |
| NCT02893917 | ACTIVE_NOT_RECRUITING | Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma With Neuroendocrine Differentiation; Stage IV Prostate Adenocarcinoma AJCC v7 |
National Cancer Institute (NCI) |
2017-08-11 | PHASE2 |
| NCT03570437 | UNKNOWN | Carcinosarcoma; Endometrial Neoplasms |
University of Manchester |
2018-05-17 | PHASE2 |
| NCT04739800 | ACTIVE_NOT_RECRUITING | Fallopian Tube Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Platinum-Refractory Fallopian Tube Carcinoma; Platinum-Refractory Ovarian Carcinoma; Platinum-Refractory Primary Peritoneal Carcinoma; Recurrent Fallopian Tube Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Endometrioid Adenocarcinoma; Recurrent Fallopian Tube High Grade Serous Adenocarcinoma; Recurrent Fallopian Tube Mucinous Adenocarcinoma; Recurrent Fallopian Tube Transitional Cell Carcinoma; Recurrent Fallopian Tube Undifferentiated Carcinoma; Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma; Recurrent Ovarian Clear Cell Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Ovarian High Grade Serous Adenocarcinoma; Recurrent Ovarian Low Grade Serous Adenocarcinoma; Recurrent Ovarian Mucinous Adenocarcinoma; Recurrent Ovarian Seromucinous Carcinoma; Recurrent Ovarian Transitional Cell Carcinoma; Recurrent Ovarian Undifferentiated Carcinoma; Recurrent Platinum-Resistant Fallopian Tube Carcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma; Recurrent Platinum-Resistant Primary Peritoneal Carcinoma; Recurrent Primary Peritoneal Clear Cell Adenocarcinoma; Recurrent Primary Peritoneal Endometrioid Adenocarcinoma; Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma; Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma; Recurrent Primary Peritoneal Transitional Cell Carcinoma; Recurrent Primary Peritoneal Undifferentiated Carcinoma; Refractory Fallopian Tube Clear Cell Adenocarcinoma; Refractory Fallopian Tube Endometrioid Adenocarcinoma; Refractory Fallopian Tube High Grade Serous Adenocarcinoma; Refractory Fallopian Tube Mucinous Adenocarcinoma; Refractory Fallopian Tube Transitional Cell Carcinoma; Refractory Fallopian Tube Undifferentiated Carcinoma; Refractory Low Grade Fallopian Tube Serous Adenocarcinoma; Refractory Ovarian Clear Cell Adenocarcinoma; Refractory Ovarian Endometrioid Adenocarcinoma; Refractory Ovarian High Grade Serous Adenocarcinoma; Refractory Ovarian Low Grade Serous Adenocarcinoma; Refractory Ovarian Mucinous Adenocarcinoma; Refractory Ovarian Seromucinous Carcinoma; Refractory Ovarian Transitional Cell Carcinoma; Refractory Ovarian Undifferentiated Carcinoma; Refractory Primary Peritoneal Clear Cell Adenocarcinoma; Refractory Primary Peritoneal Endometrioid Adenocarcinoma; Refractory Primary Peritoneal High Grade Serous Adenocarcinoma; Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma; Refractory Primary Peritoneal Transitional Cell Carcinoma; Refractory Primary Peritoneal Undifferentiated Carcinoma |
National Cancer Institute (NCI) |
2021-06-10 | PHASE2 |
| NCT02974621 | ACTIVE_NOT_RECRUITING | Recurrent Glioblastoma |
National Cancer Institute (NCI) |
2017-12-07 | PHASE2 |
| NCT03699449 | UNKNOWN | Platinum-resistant Recurrent Ovarian Cancer |
Yonsei University |
2018-11-26 | PHASE2 |
| NCT02345265 | ACTIVE_NOT_RECRUITING | Fallopian Tube Carcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Ovarian Carcinoma; Ovarian High Grade Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal Carcinoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma |
National Cancer Institute (NCI) |
2016-05-23 | PHASE2 |
| NCT02498613 | ACTIVE_NOT_RECRUITING | Advanced Malignant Solid Neoplasm; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Small Cell Carcinoma; Metastatic Pancreatic Adenocarcinoma; Metastatic Triple-Negative Breast Carcinoma; Pancreatic Ductal Adenocarcinoma; Stage III Breast Cancer AJCC v7; Stage III Lung Non-Small Cell Cancer AJCC v7; Stage III Lung Small Cell Carcinoma AJCC v7; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Small Cell Carcinoma AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IIIB Lung Small Cell Carcinoma AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Lung Non-Small Cell Cancer AJCC v7; Stage IV Lung Small Cell Carcinoma AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Triple-Negative Breast Carcinoma; Unresectable Lung Small Cell Carcinoma; Unresectable Pancreatic Adenocarcinoma; Unresectable Pancreatic Carcinoma; Unresectable Triple-Negative Breast Carcinoma |
National Cancer Institute (NCI) |
2016-08-31 | PHASE2 |
| NCT02681237 | COMPLETED | Ovarian Cancer |
University Health Network, Toronto |
2016-04-29 | |
| NCT02855697 | COMPLETED | Ovarian Cancer |
The Christie NHS Foundation Trust |
2017-05-26 | EARLY_PHASE1 |
| NCT04184518 | WITHDRAWN | Uveal Melanoma; Metastatic Cancer |
Grupo Español Multidisciplinar de Melanoma |
2020-05 | PHASE2 |
| NCT03314740 | COMPLETED | Ovarian Neoplasms |
Mario Negri Institute for Pharmacological Research |
2017-06-12 | PHASE2 |
| NCT03117933 | COMPLETED | Ovarian Cancer |
University of Oxford |
2017-03-09 | PHASE2 |
| NCT04184518 | Withdrawn | Uveal Melanoma|Metastatic Cancer |
Grupo Español Multidisciplinar de Melanoma|MFAR |
2020-05 | Phase 2 |
| NCT02899728 | TERMINATED | Extensive Stage Lung Small Cell Carcinoma |
National Cancer Institute (NCI) |
2018-03-30 | PHASE2 |
| NCT02446600 | ACTIVE_NOT_RECRUITING | Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Tumor; Ovarian Seromucinous Carcinoma; Ovarian Serous Tumor; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Primary Peritoneal Carcinoma |
National Cancer Institute (NCI) |
2016-03-28 | PHASE3 |
| NCT01208051 | COMPLETED | Refractory Differentiated Thyroid Gland Carcinoma; Refractory Thyroid Gland Follicular Carcinoma; Refractory Thyroid Gland Hurthle Cell Carcinoma; Refractory Thyroid Gland Papillary Carcinoma; Unresectable Thyroid Gland Carcinoma |
National Cancer Institute (NCI) |
2010-09-09 | PHASE1; PHASE2 |
| NCT02889900 | COMPLETED | Recurrent Platinum Resistant Ovarian Cancer |
AstraZeneca |
2017-01-17 | PHASE2 |
| NCT01337401 | UNKNOWN | Alveolar Soft-part Sarcoma |
Institute of Cancer Research, United Kingdom |
2011-07 | PHASE2 |
| NCT01364051 | ACTIVE_NOT_RECRUITING | Metastatic Melanoma; Refractory Malignant Solid Neoplasm; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Malignant Solid Neoplasm |
National Cancer Institute (NCI) |
2011-05-25 | PHASE1 |
| NCT01116648 | ACTIVE_NOT_RECRUITING | Fallopian Tube Carcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Serous Surface Papillary Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Triple-Negative Breast Carcinoma |
National Cancer Institute (NCI) |
2010-04-14 | PHASE1; PHASE2 |
| NCT00942877 | COMPLETED | Sarcoma, Alveolar Soft Part |
National Cancer Institute (NCI) |
2009-07-18 | PHASE2 |
| NCT01064648 | ACTIVE_NOT_RECRUITING | Epithelioid Mesothelioma; Pleural Malignant Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma |
National Cancer Institute (NCI) |
2010-03-15 | PHASE1; PHASE2 |
| NCT02340611 | COMPLETED | Ovarian Cancer |
University Health Network, Toronto |
2015-06 | PHASE2 |
| NCT01132820 | COMPLETED | Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma |
National Cancer Institute (NCI) |
2010-06 | PHASE2 |
| NCT01062425 | COMPLETED | Adult Glioblastoma; Adult Gliosarcoma |
National Cancer Institute (NCI) |
2010-02-26 | PHASE2 |
| NCT00326664 | COMPLETED | Childhood Atypical Teratoid/Rhabdoid Tumor; Childhood Central Nervous System Germ Cell Tumor; Childhood Cerebral Anaplastic Astrocytoma; Childhood Cerebral Astrocytoma; Childhood Grade I Meningioma; Childhood Grade II Meningioma; Childhood Grade III Meningioma; Childhood Infratentorial Ependymoma; Childhood Oligodendroglioma; Childhood Spinal Cord Neoplasm; Childhood Supratentorial Ependymoma; Recurrent Childhood Brain Neoplasm; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Ependymoma; Recurrent Childhood Medulloblastoma; Recurrent Childhood Pineoblastoma; Recurrent Childhood Subependymal Giant Cell Astrocytoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor; Recurrent Childhood Visual Pathway Glioma |
National Cancer Institute (NCI) |
2006-03 | PHASE1 |
| NCT02484404 | Recruiting | Colorectal Neoplasms|Breast Neoplasms |
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
2015-06-29 | Phase 1|Phase 2 |
| NCT01131234 | COMPLETED | Adult Anaplastic Astrocytoma; Adult Anaplastic Ependymoma; Adult Anaplastic Oligodendroglioma; Adult Brain Stem Glioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Solid Neoplasm; Male Breast Carcinoma; Recurrent Adult Brain Neoplasm; Recurrent Breast Carcinoma; Recurrent Colon Carcinoma; Recurrent Melanoma; Recurrent Non-Small Cell Lung Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Ovarian Germ Cell Tumor; Recurrent Pancreatic Carcinoma; Recurrent Rectal Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Pancreatic Cancer; Stage III Renal Cell Cancer; Stage IIIA Colon Cancer; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Ovarian Germ Cell Tumor; Stage IIIA Rectal Cancer; Stage IIIA Skin Melanoma; Stage IIIB Breast Cancer; Stage IIIB Colon Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Ovarian Germ Cell Tumor; Stage IIIB Rectal Cancer; Stage IIIB Skin Melanoma; Stage IIIC Breast Cancer; Stage IIIC Colon Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Ovarian Germ Cell Tumor; Stage IIIC Rectal Cancer; Stage IIIC Skin Melanoma; Stage IV Breast Cancer; Stage IV Non-Small Cell Lung Cancer; Stage IV Ovarian Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Pancreatic Cancer; Stage IV Renal Cell Cancer; Stage IV Skin Melanoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer |
National Cancer Institute (NCI) |
2010-05 | PHASE1 |
| NCT00662506 | COMPLETED | Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma |
National Cancer Institute (NCI) |
2008-04 | PHASE1; PHASE2 |
| NCT01229111 | TERMINATED | Adult Primary Cholangiocellular Carcinoma; Advanced Adult Primary Liver Cancer; Cholangiocarcinoma of the Extrahepatic Bile Duct; Cholangiocarcinoma of the Gallbladder; Localized Unresectable Adult Primary Liver Cancer; Periampullary Adenocarcinoma; Recurrent Adult Primary Liver Cancer; Recurrent Extrahepatic Bile Duct Cancer; Recurrent Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Cancer; Unresectable Gallbladder Cancer |
National Cancer Institute (NCI) |
2010-10 | PHASE2 |
| NCT00458731 | COMPLETED | Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Childhood Burkitt Lymphoma; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Progressive Hairy Cell Leukemia, Initial Treatment; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Hairy Cell Leukemia; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IVA Mycosis Fungoides/Sezary Syndrome; Stage IVB Mycosis Fungoides/Sezary Syndrome; T-cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific; Waldenström Macroglobulinemia |
National Cancer Institute (NCI) |
2007-05 | PHASE1 |
| NCT01160926 | TERMINATED | Rectal Cancer |
The Christie NHS Foundation Trust |
2010-07 | PHASE1 |
| NCT01065662 | COMPLETED | Endometrial Cancer; Ovarian Cancer; Cervical Cancer; Fallopian Tube Cancer; Peritoneal Cancer |
Susana M. Campos, MD |
2010-02 | PHASE1 |
| NCT00410904 | COMPLETED | Recurrent Non-small Cell Lung Cancer |
National Cancer Institute (NCI) |
2006-10 | PHASE2 |
| NCT00458978 | COMPLETED | Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Laryngeal Squamous Cell Carcinoma; Stage IV Laryngeal Verrucous Carcinoma; Stage IV Lip and Oral Cavity Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Stage IV Oral Cavity Verrucous Carcinoma; Stage IV Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary |
National Cancer Institute (NCI) |
2007-02 | PHASE2 |
| NCT00227760 | COMPLETED | Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer |
National Cancer Institute (NCI) |
2005-12 | PHASE2 |
| NCT01310855 | TERMINATED | Glioblastoma |
University College, London |
2011-05 | PHASE2 |
| NCT00532194 | UNKNOWN | Ovarian Cancer |
Medical Research Council |
2007-07 | PHASE3 |
| NCT01260688 | COMPLETED | Hormone Refractory Prostate Cancer; Recurrent Prostate Cancer |
National Cancer Institute (NCI) |
2010-10 | PHASE2 |
| NCT01229930 | COMPLETED | Cervical Cancer |
University of Glasgow |
2010-06 | PHASE2 |
| NCT00939848 | COMPLETED | Biliary Tract Neoplasms |
University College, London |
2011-04 | PHASE2; PHASE3 |
| NCT00527124 | TERMINATED | Adenocarcinoma of the Prostate; Stage IV Prostate Cancer |
National Cancer Institute (NCI) |
2007-11 | PHASE2 |
| NCT00979862 | COMPLETED | Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Neoplasm |
National Cancer Institute (NCI) |
2010-03 | PHASE1 |
| NCT00305656 | COMPLETED | Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor |
National Cancer Institute (NCI) |
2006-01 | PHASE2 |
| NCT00243061 | COMPLETED | Acral Lentiginous Malignant Melanoma; Ciliary Body and Choroid Melanoma, Medium/Large Size; Ciliary Body and Choroid Melanoma, Small Size; Extraocular Extension Melanoma; Intraocular Melanoma; Iris Melanoma; Lentigo Maligna Malignant Melanoma; Recurrent Melanoma; Stage, Intraocular Melanoma; Stage IV Melanoma; Superficial Spreading Malignant Melanoma |
National Cancer Institute (NCI) |
2006-01 | PHASE2 |
| NCT00795340 | COMPLETED | Lung Cancer |
NCIC Clinical Trials Group |
2009-02-04 | PHASE3 |
| NCT01262612 | TERMINATED | Malignant Ascites; Malignant Pleural Effusion |
Radboud University Medical Center |
2010-04 | PHASE2 |
| NCT00326872 | TERMINATED | Neurofibromatosis Type 1; Plexiform Neurofibroma; Spinal Cord Neurofibroma |
National Cancer Institute (NCI) |
2006-05 | PHASE2 |
| NCT00475150 | COMPLETED | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Untreated Adult Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2008-05 | PHASE2 |
| NCT01391962 | Active not recruiting | Sarcoma Alveolar Soft Part |
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
2011-07-18 | Phase 2 |
| NCT01337401 | Unknown status | Alveolar Soft-part Sarcoma |
Institute of Cancer Research United Kingdom|Royal Marsden NHS Foundation Trust |
2011-07 | Phase 2 |
| NCT00303862 | TERMINATED | Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer |
National Cancer Institute (NCI) |
2006-03 | PHASE2 |
| NCT00937482 | TERMINATED | Male Breast Cancer; Stage IV Breast Cancer; Stage IV Melanoma; Stage IV Non-small Cell Lung Cancer; Stage IV Renal Cell Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer; Tumors Metastatic to Brain |
National Cancer Institute (NCI) |
2009-08 | PHASE1 |
| NCT00309946 | COMPLETED | Advanced Malignant Mesothelioma; Epithelial Mesothelioma; Localized Malignant Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatous Mesothelioma |
National Cancer Institute (NCI) |
2005-12 | PHASE2 |
| NCT00621725 | COMPLETED | Advanced Cancer; Hepatic Impairment |
AstraZeneca |
2008-01 | PHASE1 |
| NCT01160926 | Terminated | Rectal Cancer |
The Christie NHS Foundation Trust|Cancer Research UK|AstraZeneca |
2010-07 | Phase 1 |
| NCT00278343 | COMPLETED | Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer |
National Cancer Institute (NCI) |
2006-04 | PHASE2 |
| NCT00588900 | TERMINATED | Colorectal Cancer |
Alliance for Clinical Trials in Oncology |
2008-03 | PHASE2 |
| NCT00981721 | COMPLETED | Advanced Solid Malignancies |
AstraZeneca |
2009-09 | PHASE1 |
| NCT00427973 | TERMINATED | Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer |
National Cancer Institute (NCI) |
2009-05 | PHASE2 |
| NCT00777153 | COMPLETED | Recurrent Glioblastoma |
AstraZeneca |
2008-10 | PHASE3 |
| NCT00243074 | COMPLETED | Advanced Malignant Mesothelioma; Epithelial Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatous Mesothelioma |
National Cancer Institute (NCI) |
2005-11 | PHASE2 |
| NCT00399035 | COMPLETED | Metastatic Colorectal Cancer |
AstraZeneca |
2006-11 | PHASE3 |
| NCT00275028 | COMPLETED | Fallopian Tube Cancer; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Epithelial Cancer; Stage I Ovarian Epithelial Cancer; Stage II Ovarian Epithelial Cancer |
National Cancer Institute (NCI) |
2005-10 | PHASE2 |
| NCT00245063 | COMPLETED | Recurrent Non-small Cell Lung Cancer |
National Cancer Institute (NCI) |
2006-03 | PHASE2 |
| NCT00436956 | COMPLETED | Prostate Cancer |
National Cancer Institute (NCI) |
2006-10-16 | PHASE2 |
| NCT00748891 | COMPLETED | Cancer |
AstraZeneca |
2008-08 | PHASE1 |
| NCT00960349 | COMPLETED | Gastric Cancer |
AstraZeneca |
2009-08 | PHASE1 |
| NCT00384176 | COMPLETED | Colorectal Cancer |
AstraZeneca |
2006-08-30 | PHASE2; PHASE3 |
| NCT00107250 | COMPLETED | Colorectal Cancer; Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
NCIC Clinical Trials Group |
2005-01-21 | PHASE1 |
| NCT00494221 | COMPLETED | Metastatic Colorectal Cancer |
AstraZeneca |
2007-06 | PHASE1; PHASE2 |
| NCT00621361 | COMPLETED | Lung Cancer |
AstraZeneca |
2008-02 | PHASE1 |
| NCT00750841 | ACTIVE_NOT_RECRUITING | Solid Tumors |
AstraZeneca |
2008-09-09 | PHASE1 |
| NCT00326599 | COMPLETED | Lung Cancer |
Alliance for Clinical Trials in Oncology |
2007-06 | PHASE2 |
| NCT00750425 | COMPLETED | Advanced Solid Tumors |
AstraZeneca |
2008-08 | PHASE1 |
| NCT00503204 | COMPLETED | Recurrent Glioblastoma; Brain Tumor |
AstraZeneca |
2007-09 | PHASE1 |
| NCT00454805 | COMPLETED | Advanced Breast Cancer |
AstraZeneca |
2007-03 | PHASE2 |
| NCT00475956 | COMPLETED | Neoplasms |
AstraZeneca |
2007-05 | PHASE1 |
| NCT00539331 | TERMINATED | Carcinoma, Non-Small-Cell Lung |
AstraZeneca |
2007-09 | PHASE1 |
| NCT00245154 | COMPLETED | Lung Cancer |
NCIC Clinical Trials Group |
2005-11-03 | PHASE2; PHASE3 |
| NCT00385203 | COMPLETED | Gastrointestinal Stromal Tumors; Soft Tissue Sarcomas |
AstraZeneca |
2006-09 | PHASE2 |
| NCT00243347 | COMPLETED | Carcinoma; Non-Small-Cell Lung Carcinoma; Head and Neck Neoplasms |
AstraZeneca |
2005-12 | PHASE1 |
| NCT00423332 | COMPLETED | Renal Cell Carcinoma |
AstraZeneca |
2007-01 | PHASE2 |
| NCT00306891 | COMPLETED | Cancer |
AstraZeneca |
2006-06 | PHASE2 |
| NCT00502567 | COMPLETED | Advanced Solid Tumor |
AstraZeneca |
2005-01 | PHASE1 |
| NCT00278889 | COMPLETED | Colorectal Cancer |
AstraZeneca |
2006-01 | PHASE2 |
| NCT00343408 | COMPLETED | Colorectal Cancer; Lung Cancer |
NCIC Clinical Trials Group |
2005-11-29 | PHASE1 |
| NCT00244881 | COMPLETED | Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer |
National Cancer Institute (NCI) |
2005-09 | PHASE2 |
| NCT00503477 | COMPLETED | Advanced Solid Tumor |
AstraZeneca |
2005-10 | PHASE1 |
| NCT00321724 | COMPLETED | B-cell Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia |
National Cancer Institute (NCI) |
2006-05 | PHASE2 |
| NCT00238394 | COMPLETED | Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer |
National Cancer Institute (NCI) |
2005-12 | PHASE2 |
| NCT00264004 | COMPLETED | Tumors |
AstraZeneca |
2005-11 | PHASE2 |
| NCT00502060 | COMPLETED | Advanced Tumor |
AstraZeneca |
2004-08 | PHASE1 |
| NCT00501605 | COMPLETED | Advanced Solid Tumor; Liver Metastases |
AstraZeneca |
2003-02 | PHASE1 |
| NCT00310089 | COMPLETED | Breast Cancer |
National Cancer Institute (NCI) |
2006-01 | |
| NCT00321581 | COMPLETED | Refractory or Recurrent Solid Tumors; Acute Myelogenous Leukemia |
National Cancer Institute (NCI) |
2006-05-01 | PHASE1 |
| NCT00502164 | COMPLETED | Advanced Prostate Adenocarcinoma |
AstraZeneca |
2004-03 | PHASE1 |
| NCT00502385 | COMPLETED | Leukaemia; Myelocytic; Acute |
AstraZeneca |
2004-04 | PHASE1 |
| NCT00503412 | COMPLETED | Advanced Solid Metastatic Tumor |
AstraZeneca |
2005-11 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-03-05)
Check the
Cediranib (AZD2171)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Cediranib (AZD2171) Solubility in DMSO
- Cediranib (AZD2171) Stock Solution
- Cediranib (AZD2171) Storage
- Cediranib (AZD2171) Stability
- Cediranib (AZD2171) Molecular Weight
- Cediranib (AZD2171) SMILES
- Cediranib (AZD2171) CAS Number
- Cediranib (AZD2171) Chemical Structure (2D and 3D)
- Cediranib (AZD2171) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.